Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
University of Pittsburgh
University of Pittsburgh
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Hummingbird Bioscience
Bristol-Myers Squibb
National Cancer Institute (NCI)
NRG Oncology
Amgen
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Gustave Roussy, Cancer Campus, Grand Paris
University of Chicago
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
R-Pharm
R-Pharm
Mayo Clinic
Shanghai Miracogen Inc.
Massachusetts General Hospital
Sun Yat-sen University
Oscotec Inc.
Sun Yat-sen University
Shanghai Miracogen Inc.
ImmunityBio, Inc.
Eye & ENT Hospital of Fudan University
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Gilead Sciences
University of Southern California
Mayo Clinic
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Rakuten Medical, Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
Hokkaido University Hospital
Groupe Oncologie Radiotherapie Tete et Cou
Groupe Oncologie Radiotherapie Tete et Cou
Memgen, Inc.
Merck Sharp & Dohme LLC
GERCOR - Multidisciplinary Oncology Cooperative Group
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NuCana plc
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Akeso
OncoC4, Inc.
Thomas Jefferson University